Charmcare Tabletop Pulse Oximeter is portable device indicated for use in non-invasively measuring and displaying functional oxygen saturation of arterial hemoglobin (SpO2) and pulse rate of adult and pediatric patients via finger in hospitals, medical facilities, and subacute environments. Pediatric population in this 510(K) application is defined as 'infant' and 'child' which are ages from 1 month to 12 years according to the guidance 'Premarket Assessment of Pediatric Medical Devices' section IV. Charmcare Tabletop Pulse Oximeter is intended for spot-checking and / or continuous monitoring of patients, the sensor of device is reusable or disposable.

Device Description

The device works by applying a sensor to a pulsating arteriolar vascular bed. The sensor contains a dual light source and photo detector. The one wavelength of light source is 660 nm, which is red light; the other is 940 nm, which is ultra red light. Skin, bone, tissue and venous vessels normally absorb a constant amount of light during systole and diastole, as blood volume increases and decreases. The ratio of light absorbed at systole and diastole into an oxygen saturation measurement. This measurement is referred to as SpO2. This applicant device of Accuro is the desktop pulse oximeter monitor, which mainly function are measurement, display, alarm, data storage.

AI/ML Overview

Here's a breakdown of the acceptance criteria and study details for the Charmcare Tabletop Pulse Oximeter, based on the provided 510(k) summary:

Acceptance Criteria and Reported Device Performance

Test	Acceptance Criteria	Reported Device Performance
SpO2 Test (Non-clinical)	100-70% SpO2: error within ±2%70-30% SpO2: error within ±3%	Accuro passed the performance criteria in the entire SpO2 range (100-30%) for all pulse rates (60, 150, 250 bpm) and average time modes (2, 4, 8, 12 seconds).
Pulse Rate Test (Non-clinical)	Error within ±2 bpm	Accuro passed the performance criteria in the entire Pulse Rate range (30-250 bpm) for all average time modes (2, 4, 8, 12 seconds).
Electrical, Mechanical, and Environmental Tests	Defined in individual test reports (e.g., IEC 6061-1, ISO 9919, FCC Part 15, ISO 10993-10)	Accuro passed all criteria specified in the relevant standards.
Clinical SaO2 vs. SpO2 RMS Error (for SpO2 70-100%)	Less than or slightly above 2% (Charmcare's own criteria, and comparable to predicate device N-395)	Adult Sensor: 1.72Disposable Sensor: 2.37Pediatric Sensor: 2.61Overall RMS error: 2.21

Study Details that Prove the Device Meets Acceptance Criteria

Sample Size Used for the Test Set and Data Provenance:
- Non-clinical tests (SpO2 and Pulse Rate): The testing involved using a Fluke Index2 SpO2 simulator with varying SpO2 and Pulse Rate settings. This is a controlled, simulated environment, not human data.
- Clinical Data: 10 subjects (7 women, 3 men).
- Data Provenance: The study was conducted by Charmcare Co., Ltd. for their 510(k) submission, suggesting it was likely conducted in South Korea where the company is located. The nature of the study being for regulatory submission indicates it was a prospective study designed specifically to evaluate the device.
Number of Experts Used to Establish the Ground Truth for the Test Set and Their Qualifications:
- Non-clinical tests: For simulator-based tests, the "ground truth" is the known, highly accurate output of the Fluke Index2 SpO2 simulator. No human experts are involved in establishing this ground truth.
- Clinical Data: The text states, "The rms error between SaO2 and SpO2 was calculated for each sensor." SaO2 (arterial oxygen saturation) measurements taken from blood samples are generally considered the gold standard for ground truth in this context. While not explicitly stated, these measurements would typically be performed by trained lab personnel, and potentially overseen by medical professionals, but not necessarily "experts" in the sense of a consensus panel. The document does not specify the number of experts or their qualifications for establishing the SaO2 ground truth.
Adjudication Method for the Test Set:
- Non-clinical tests: Not applicable, as the comparison is directly between the device's reading and the simulator's known output.
- Clinical Data: Not applicable. The ground truth (SaO2) is an objective measurement from blood samples, not subject to individual interpretation or adjudication by multiple human readers.
If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done:
- No. The studies described are focused on the device's accuracy against a simulator or against objective clinical measurements (SaO2), not on how human readers perform with or without AI assistance.
If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done:
- Yes, implicitly. The entire evaluation (both non-clinical and clinical) assesses the performance of the Charmcare Tabletop Pulse Oximeter device itself, which includes its internal algorithms for SpO2 and pulse rate calculation. There is no mention of a human operator making interpretations or decisions based on the device's output that would then be compared to a "human-in-the-loop" scenario. The "clinical data" section directly compares the device's SpO2 output (algorithm-derived) to SaO2 (ground truth).
The Type of Ground Truth Used:
- Non-clinical tests: Simulator output (Fluke Index2 SpO2 simulator).
- Clinical Data: SaO2 measurements (arterial oxygen saturation) from blood samples. This is considered an objective physiological measurement or outcomes data (in the sense of direct measurement of the physiological parameter).
The Sample Size for the Training Set:
- The document does not specify a separate training set or its size. This is typical for medical devices that utilize established physiological algorithms rather than complex machine learning models that require distinct training sets. The algorithms for pulse oximetry are based on known spectrophotometric principles, not typically "trained" on large datasets in the modern AI sense.
How the Ground Truth for the Training Set Was Established:
- Not applicable, as a distinct training set (in the context of machine learning) is not described or implied for this device's type of technology. The device's algorithms are based on fundamental principles of light absorption and oxygen saturation, which are well-established.

Summary

{0}------------------------------------------------

510(K) Summary

K092641

Submitter:

Charmcare Co., Ltd. Son Hong Ju 918 Ho Woolim Lions 2-cha, Gasan-dong Geumcheon-gu, Seoul, 153-023 Seoul 153-023. South Korea Phone: 82-02-862-5052 Fax: 82-02-862-5065

Official Correspondent: Kodent Inc. Joyce Bang 325 N. Puente St. Unit B Brea, CA 92821 Email: kodentinc@gmail.com Phone: 714-525-0114 Fax: 714-525-0116

OCT 2 1 2010

Device Information

Trade Name: Charmcare Tabletop Pulse Oximeter Regulation Description: Oximeter Product Code: DQA Regulation Number: 870.2700 Device Class: Class II

Device Description

Indication for Use

{1}------------------------------------------------

Predicate Devices

The subject device is substantially equivalent to the following predicate devices:

N-395 Pulse Oximeter (K991823) manufactured by Nellcor Puritan Bennett Inc. .

Comparison to Predicate Devices

Substantial equivalence to the following legally marketed predicate devices with the same of similar indications for use has been demonstrated by a comparison of product features as described in the labeling and promotional literature for predicate devices and for the N-395, as well as testing to accepted industry standards. In addition, in-vitro and non-invasive controlled hypoxia studies were conducted to establish the Accuracy and to ensure that the sensors meet their currently published accuracy specifications with the Accuro.

Non-clinical performance test summary - Refer to the "Accuro System Test Form"

· Spo2 test
· Method : The sensor of Accuro was connected to the Fluke Index2 Spo2 simulator. As the SpO2 setting value of the simulator changed from 100% to 30% with steps of 2% per minutes. The difference(error) between SpO2 value of simulator and that of Accuro was calculated. This cycle was repeated for Pulse Rate of 60, 150, 250bpm and average time of 2. 4. 8, 12 seconds.

Criteria : SpO2 100~~70% : error within ±2% / SpO2 70~~30% : error within ±3%

Result : Accuro passed the performance criteria in entire SpO2 range for all the pulse rate and average time modes.
· Pulse Rate test
Method : With SpO2 value of the Index2 simulator fixed to 98%, Pulse Rate of the simulator changed from 250bpm to 30bpm. The difference(error) between the pulse rate value of simulator and that of Accuro was calculated. This cycle was repeated for average time = 2, 4, 8, 12 seconds
Criteria : error within ±2bpm

Result : Accuro passed the performance criteria in entire Pulse Rate range for all average time modes.

· Electrical, mechanical , and environmental tests

For the test methods and acceptance criteria, refer to each test report.

{2}------------------------------------------------

Safety : IEC 6061-1. ISO 9919

Electrical : FCC Part 15, Section 15.109, Class B

Biacompatibility : ISO 10993-10

Result : Accuro passed all criteria

2) Evaluation of the difference between Accuro and N-395 devices

Nellcor N-395 adopts SatSeconds algorithm for alarm management which is to suppress alarm when the SpO2 de-saturation is not too severe or the duration is short. The main purpose of this scheme is to remove the effect of unserious short duration 'glitches' and functions as motion filtering.

Similarly, Charmcare Tabletop Pulse Oximeter adopts alarm management system which prevents incorrect alarms caused either by 'glitches' or motion. First, Charmcare Tabletop Pulse Oximeter adopts special type moving average algorithm to remove the effect of glitches in SpO2 or pulse rate. The device takes average from recently acquired sample values are sorted and samples near the lower or higher limits are filtered before averaging so that the effect of glitch is eliminated. Second, digital signal processing algorithm filters out invalid frequency domain components arising from motion. If the filtering continues over a pre-determined time, the device considers that it is a motion situation. Then, the device suppresses alarms and displays motion indication. In this way, Charmcare Tabletop Pulse Oximeter implements equivalent alarm management and motion filtering functions as the Nellcor N-395 Pulse Oximeter.

3) Summary of the clinical data

The clinical test for Accuro included 10 subjects- 7 women and 3 men. The Accuro oximeter was studied with neonate, adult, disposable, and pediatric sensors (neonate is not included in the intend for use of this device). Healthy non-smoking individuals of age 21-49 were included in the study. The skin colors were composed of 1 dark, 3 medium, and 6 light colors. Some subjects showed low perfusion index for some specific SpO2 ranges, usually below 80%.

The rms error between SaO2 and SpO2 was calculated for each sensor.

For SpO2 70~100%, rms error of each sensor was

Adult Sensor : 1.72 / Disposable Sensor : 2.37 / Pediatric Sensor : 2.61

Overall rms error : 2.21

{3}------------------------------------------------

The test showed that rms errors of disposable sensor were slightly bigger than the error limit of performance test stated above (2% for 70~100%). This deviation was mainly due to low perfusion index of some subjects, which resulted in unreliable signal input. Another reason was that the averaging algorithm of the Accuro required settling time of SpO2 values when there was a change in the saturation level. If there was a relatively big change of the saturation level in a short time, a temporary gap between the SpO2 and SaO2 values was caused.

In spite of the adverse events stated above. the rms error of the clinical test was less than or slightly above the performance test criteria of Charmcare, which is 2%. The predicate device N-395 also shows 2% error limit for adults in the SpO2 range from 70% to 100%. According to this comparison, Charmcare pulse oximeter showed substantial equivalence to the predicative device N-395.

Conclusion

The Charmcare pulse oximeter, subject of this submission, constitutes a safe, reliable and effective medical device, meeting all the declared requirements of its intended use. Device presents no safety risks to patients when used as intended. This system has the same intended use and fundamental scientific technology as its predicate devices. Therefore, Charmcare pulse oximeter and its predicate devices are believed to be substantially equivalent.

{4}------------------------------------------------

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002

Charmcare Company, Limited C/O Ms. Joyce Bang Kodent, Incorporated 325N. Puente St. Unit B Brea, California 92821

OCT 2 1 2010

Re: K092641

Trade/Device Name: Charmcare Tabletop Pulse Oximeter Regulation Number: 21 CFR 870.2700 Regulation Name: Oximeter Regulatory Class: II Product Code: DOA Dated: September 17, 2010 · Received: October 14, 2010

Dear Ms. Bang:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{5}------------------------------------------------

Page 2- Ms. Bang

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to

http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.

Sincerely your

Anthony D. Watson, B.S., M.S., M.B.A. Director

Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

{6}------------------------------------------------

KO92641 510(K) Number (if known):

OCT 2 1 2010

Device Name: Charmcare Tabletop Pulse Oximeter

Indication for Use:

Prescription Use X

AND/OR

Over-The-Counter - - -

(Part 21 CFR 801 Subpart D)

(Per 21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device,Evaluat

Page 1 of 1

(Division Sign-Off) (Division Sign-Off)
Division of Anesthesiology, General Hospital
Division of Anesthesiology, General Povioes Division Control, Dental Devices

5 510(k) Number: k 09264

Regulation Number and Section

§ 870.2700 Oximeter.

(a)
Identification. An oximeter is a device used to transmit radiation at a known wavelength(s) through blood and to measure the blood oxygen saturation based on the amount of reflected or scattered radiation. It may be used alone or in conjunction with a fiberoptic oximeter catheter.(b)
Classification. Class II (performance standards).